Vaccinex, Inc. (VCNX): Price and Financial Metrics
VCNX Price/Volume Stats
| Current price | $4.96 | 52-week high | $100.80 |
| Prev. close | $4.94 | 52-week low | $4.43 |
| Day low | $4.81 | Volume | 7,400 |
| Day high | $5.10 | Avg. volume | 11,669 |
| 50-day MA | $7.76 | Dividend yield | N/A |
| 200-day MA | $21.37 | Market Cap | 6.11M |
VCNX Stock Price Chart Interactive Chart >
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Latest VCNX News From Around the Web
Below are the latest news stories about VACCINEX INC that investors may wish to consider to help them evaluate VCNX as an investment opportunity.
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleCompany Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer, previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in comp |
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePhase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial r |
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingPepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanomaROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy |
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesPepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, MA. Vaccinex has previously re |
Why Is Omniq (OMQS) Stock Down 43% Today?Omniq shares are taking a beating on Friday after the company announced the details of a $3 million public offering for OMQS stock. |
VCNX Price Returns
| 1-mo | -36.04% |
| 3-mo | -39.97% |
| 6-mo | -63.06% |
| 1-year | -93.86% |
| 3-year | -99.04% |
| 5-year | -99.65% |
| YTD | -46.71% |
| 2023 | -93.12% |
| 2022 | -38.03% |
| 2021 | -49.76% |
| 2020 | -57.32% |
| 2019 | 33.06% |
Continue Researching VCNX
Want to do more research on Vaccinex Inc's stock and its price? Try the links below:Vaccinex Inc (VCNX) Stock Price | Nasdaq
Vaccinex Inc (VCNX) Stock Quote, History and News - Yahoo Finance
Vaccinex Inc (VCNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...